[Skip to Content]
[Skip to Content Landing]
Article
August 20, 1997

Risk of Chronic Arthropathy Among Women After Rubella Vaccination

Author Affiliations

From the Northern California Kaiser Permanente Vaccine Study Center, Oakland (Mss Ray and Schwalbe and Drs Black, Shinefield, and Dillon); the Center for Pediatric Research, Eastern Virginia Medical School, Norfolk (Dr Holmes); and the National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Ga (Drs Hadler, Chen, Cochi, and Wassilak).

JAMA. 1997;278(7):551-556. doi:10.1001/jama.1997.03550070043036
Abstract

Context.  —A review by the Institute of Medicine found a possible relationship between rubella vaccination and chronic arthritis among women.

Objective.  —To evaluate the risk of persistent joint and neurologic symptoms in rubella seronegative women subsequently vaccinated with RA 27/3 rubella vaccine.

Design.  —Retrospective cohort study based on computerized laboratory data and medical record review. Records were reviewed for symptoms occurring within 2 years before and after the date of serological testing and to identify vaccinees. Possible cases were evaluated by a rheumatologist blinded to serological findings and vaccination status.

Setting.  —Large health maintenance organization in northern California.

Patients.  —Women aged 15 to 59 years serotested for rubella during 1990 with continuous health plan membership for 2 years before and after the date of their serological test. Seronegative women immunized within 1 year of serotesting (n=971) were defined as exposed. Primary comparison groups included all unvaccinated, seronegative women (n=924) and randomly selected seropositive, unvaccinated women (n=2421) matched to exposed subjects on serological test date and age (±3 years).

Main Outcome Measures.  —Prevalence and incidence of chronic joint and neurologic symptoms during 1-year follow-up period stratified by age and serological findings, immunization, and postpartum status.

Results.  —No significantly increased risk was associated with receipt of rubella vaccine for any outcome except for prevalence of carpal tunnel syndrome in vaccinated women at least 30 years old compared with seropositive, unvaccinated women (2.9% vs 1.4%; P=.03). A total of 34 women had onset of conditions within the 1-year follow-up period; 9 of these were in the group of seronegative, immunized women, of whom 6 had onset of symptoms within 6 weeks of vaccination. Among these 6 women, symptoms included transient arthritis or arthralgias (<6 weeks duration) in 4 women, arthralgia of indeterminate chronicity in 1 woman, and carpal tunnel syndrome in 1 woman. Postpartum women across all groups were less likely to be seen for nontraumatic arthropathies than nonpostpartum women (4.5% vs 7.2%, P=.08 in vaccinated women; 4.8% vs 8.1%, P=.09 in seronegative controls; and 4.8% vs 10.0%, P=.01 in seropositive controls).

Conclusions  —In this large retrospective cohort analysis there was no evidence of any increased risk of new onset chronic arthropathies or neurologic conditions in women receiving the RA 27/3 rubella vaccine. These data support the continued vaccination of rubella-susceptible women to reduce the risk of congenital rubella syndrome.

×